Full Press Release Details
Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine.
BBIO
Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine
Key Takeaway: Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis